Emerging Treatments in HIV

Feature Article

Once-Daily Raltegravir Safe, Effective for Initial HIV Treatment

Once-Daily Raltegravir Safe, Effective for Initial HIV Treatment

Once-daily regimens have been shown to improve adherence to treatment with no adverse effect on outcomes in patients with HIV.

Latest News

Ampicillin Plus Ceftriaxone: An Effective Alternative for E faecalis Infective Endocarditis

Ampicillin Plus Ceftriaxone: An Effective Alternative for E faecalis Infective Endocarditis

Ampicillin plus ceftriaxone was an effective treatment for penicillin-susceptible Enterococcus faecalis infective endocarditis compared with ampicillin plus gentamicin.

Continuous Antibiotic Infusion via Elastomeric Pumps Safe and Effective in Outpatients

Continuous Antibiotic Infusion via Elastomeric Pumps Safe and Effective in Outpatients

Treating outpatients with continuous infusions of flucloxacillin, cefepime, vancomycin, and piperacillin/tazobactam using elastomeric pumps was effective and safe.

Could Zika Virus Be a Potential Treatment for Neuroblastoma?

Could Zika Virus Be a Potential Treatment for Neuroblastoma?

Even with intensive therapy, survival among neuroblastoma patients is poor, indicating a need for alternative treatments.

Zemdri Now Available for the Treatment of Complicated UTI, Pyelonephritis

Zemdri Now Available for the Treatment of Complicated UTI, Pyelonephritis

Zemdri carries a Boxed Warning describing reports of nephrotoxicity, ototoxicity, and neuromuscular blockade, as well as fetal harm if administered during pregnancy.

TPOXX Approved for the Treatment of Human Smallpox Disease

TPOXX Approved for the Treatment of Human Smallpox Disease

The approval was supported by findings from 12 clinical trials of TPOXX with more than 700 healthy volunteers that showed no drug-related serious adverse events.

Novel Antiretroviral Therapy Trogarzo Now Available to Treat HIV-1

Novel Antiretroviral Therapy Trogarzo Now Available to Treat HIV-1

The approval of Trogarzo was supported by a clinical trial (N=40) of heavily treatment-experienced adults with multidrug resistant HIV-1 infection who continued to have high levels of HIV RNA in their blood despite antiretroviral therapy.

Tenofovir Alafenamide Plus Emtricitabine Safely and Effectively Treats HIV-1

Tenofovir Alafenamide Plus Emtricitabine Safely and Effectively Treats HIV-1

A head-to-head comparison was made between HIV-1 treatment regimens containing tenofovir alafenamide plus emtricitabine with those containing abacavir plus lamivudine.

FDA Approves Combination Treatment Symfi for HIV-1 Infection

FDA Approves Combination Treatment Symfi for HIV-1 Infection

Symfi contains the same triple combination ingredients found in the recently approved and launched Symfi Lo but with a 600mg dose of efavirenz vs 400mg seen in Symfi Lo.

Single Tablet HIV Regimen Noninferior to Abacavir-Containing Regimen

Single Tablet HIV Regimen Noninferior to Abacavir-Containing Regimen

A phase 3 study evaluating HIV patients who switched to treatment with Biktarvy found this combination therapy to be statistically noninferior to a regimen containing abacavir,

Intravenous Drug Approved for Multidrug-Resistant HIV Infection

Intravenous Drug Approved for Multidrug-Resistant HIV Infection

The FDA has approved Trogarzo for the treatment of adults with HIV whose infections are multidrug-resistant.

Sign Up for Free e-newsletters